Lipid-lowering therapy corrects endothelial cell dysfunction in a short time but does not affect hypercoagulable state even after long-term use in hyperlipidemic patients

Blood Coagulation and Fibrinolysis

Volumn 10, Issue 5, 1999, Pages 269-276

  Kario, K ^a,d   Matsuo, T ^b   Hoshide, S ^a   Kobayashi, H ^b   Sakata, T ^c   Mizuno, O ^a   Mitsuhashi, T ^a   Ikeda, U ^a   Miyata, T ^c   Shimada, K ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b HYOGO PREFECTURAL AWAJI HOSPITAL   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Endothelial cell damage; Hypercoagulability; Hyperlipidemia; Lipid lowering therapy

Indexed keywords

ANTILIPEMIC AGENT; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; CHOLESTEROL; FIBRINOGEN; PEPTIDE FRAGMENT; PROTHROMBIN; SIMVASTATIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; ENDOTHELIUM CELL; ENDOTHELIUM LESION; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERCOAGULABILITY; HYPERLIPIDEMIA; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT OUTCOME;

EID: 0032784315     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199907000-00008     Document Type: Article

References (39)

1. 1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
2. 2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlance PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
3. 3. Brown BG, Zhao X-Q, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-1791.
4. 4. Harrison DG, Armstrong ML, Freiman PC, Heistad DD. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987; 80: 1808-1811.
5. 5. Osborne JA, Lento PH, Siegfried MR, Stahl GL, Fusman B, Lefer AM. Cardiovascular effects of acute hypercholesterolemia in rabbits: reversal with lovastatin treatment. J Clin Invest 1989; 83: 469-473.
6. 6. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995; 332: 488-493.
7. 7. Sadler EJ. von Willebrand factor. J Biol Chem 1991; 266: 22777-22780.
8. 8. Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hackeng WHL, Donker AJM, den Ottolander GJH. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-323.
9. 9. Blann AD, Naqvi T, Waite M, McCollum CN. von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens 1993; 7: 107-111.
10. 10. Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell'Omo G, Catapano G, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344: 14-18.
11. 11. Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T. Activation of tissue factor-induced coagulation and endothelial cell dysfunction of noninsulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 1995; 15:1114-1120.
12. 12. Kario K, Matsuo T, Kobayashi H, Asada R, Matsuo M. 'Silent' cerebral infarction is associated with hypercoagulability, endothelial cell damage, and high Lp(a) levels in elderly Japanese. Arterioscler Thromb Vasc Biol 1996; 16: 734-741.
13. 13. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-355.
14. 14. Blann AD Maxwell SRJ, Burrows G, Miller JP. Antioxidants, von Willebrand factor and endothelial cell injury in hypercholesterolaemia and vascular disease. Atherosclerosis 1995; 116: 191-198.
15. 15. Blann AD, Jackson P, Bath PMW, Watts GF. von Willebrand factor, a possible indicator of endothelial cell damage, decreased during long-term compliance with a lipid-lowering diet. J Intern Med 1995; 237: 557-561.
16. 16. Rapaport SI, Rao LVM. Initiation and regulation of tissue factor-dependent blood coagulation. Arterioscler Thromb 1992; 12: 1111-1121.
17. 17. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WRS, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; ii: 533-537.
18. 18. Hoffman C, Shah A, Sodums M, Hultin MB. Factor VII activity state in coronary artery disease. J Lab Clin Med 1988; 111: 475-481.
19. 19. Kario K, Matsuo T. Coronary artery disease and factor VII hyperactivity in elderly Japanese. Am J Cardiol 1992; 69: 807-809.
20. 20. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342: 1076-1079.
21. 21. Mennen LI, Schouten EG, Grobbee, DE, Kluft C. Coagulation factor VII, dietary fat and blood lipids: a review, Thromb Haemost 1996; 76: 492-499.
22. 22. Kario K, Matsuo T. Lipid-related hemostatic abnormalities in the elderly: imbalance between coagulation and fibrinolysis. Atherosclerosis 1993; 103: 131-138.
23. 23. Bauer KA Goodman TL, Kass BL, Rosenberg RD. Elevated factor Xa activity in blood of asymptomatic patients with congenital antithrombin III deficiency. J Clin Invest 1985; 76: 826-836.
24. 24. Sokolow M, Werdegar D, Kain HK, Hinman AT. Relationship between level of blood pressure measured casually and by portable recorders and severity of complications in essential hypertension. Circulation 1966; 34: 279-298.
25. 25. Kario K, Miyata T, Sakata T, Matsuo T, Kato H. Fluorogenic assay of activated factor VII: plasma factor VIIa levels in relation to arterial cardiovascular diseases in Japanese. Arterioscler Thromb 1994; 14: 265-274.
26. 26. Andrews TC, Raby K, Barry J, Naimi CL, Allred E, Ganz P, et al. Effect of cholesterol reduction in myocardial ischemia in patients with coronary disease. Circulation 1997; 95: 324-328.
27. 27. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latifi R, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipiridamole in patients with coronary artery disease: a potential noninvasive marker of healing coronary endothelium. Circulation 1994; 89: 1530-1538.
28. 28. Sandset PM, Lund H, Norseth J, Abildgaard U, Ose L. Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system. Arterioscler Thromb 1991; 11: 138-145.
29. 29. Mitropoulos KA, Armitage JM, Collins R, Meade TW, Reeves BEA, Wallendszus KR, et al., for the Oxford Cholesterol Study Group. Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acid. Eur Heart J 1997; 18: 235-241.
30. 30. DiGarbo V, Cordova R, Avellone G. Increased thrombin generation and complement activation in patients with type IIa hyperlipidemia: effects of simvastatin treatment. Curr Ther Res Clin Exp 1997; 58: 706-723.
31. 31. Slabber M, Barnard HC, Kuyl JM, Badenhorst CJ. Effect of a short-term very low calorie diet on plasma lipids, fibrinogen, and factor VII in obese subjects. Clin Biochem 1992; 25: 334-335.
32. 32. Brace LD, Gittler-Buffa C, Miller GJ, Cole TG, Schmeisser D, Prewitt TE, et al. Factor VII coagulant activity and cholesterol changes in premenopausal women consuming a long-term cholesterol-lowering diet. Arterioscler Thromb 1994; 14: 1284-1289.
33. 33. Marckmann P, Sandstrom B, Jespersen J. Favorable long-term effect of a low-fat/high-fiber diet on human blood coagulation and fibrinolysis. Arterioscler Thromb 1993; 13: 505-511.
34. 34. Humphries SE, Lane A, Green FR, Cooper J, Miller GJ. Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration. Arterioscler Thromb 1994; 14: 193-198.
35. 35. Kario K, Narita N, Matsuo T, Kayaba K, Tsutsumi A, Matsuo M, et al. Genetic determinants of plasma factor VII activity in the Japanese. Thromb Haemost 1995; 73: 617-622.
36. 36. Green F, Hamsten A, Blomback M, Humphries S. The role of beta-fibrinogen genotype in determining plasma fibrinogen levels in young survivors of myocardial infarction and healthy controls from Sweden. Thromb Haemost 1993; 70: 915-920.
37. 37. Nishiuma S, Kario K, Yakushijin K, Maeda M, Murai R, Matsuo T, et al. Genetic variation in the promoter region of the β-fibrinogen gene is associated with ischemic stroke in a Japanese population. Blood Coag Fibrinol 1998; 9: 373-379.
38. 38. Shima M, Fujimura Y, Nishiyama T, Tsujiuchi T, Narita N, Matsui T, et al. ABO blood group genotype and plasma von Willebrand factor in normal individuals. Vox Sang 1995; 68: 236-240.
39. 39. Mannucci PM. von Willebrand factor. A marker of endothelial damage? Arterioscler Thromb Vasc Biol 1998; 18: 1359-1362.